Research programme: methylthioadenosine - Digna/Avadel

Drug Profile

Research programme: methylthioadenosine - Digna/Avadel

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator Digna Biotech
  • Developer Digna Biotech; Flamel Technologies
  • Class Analgesics; Anti-inflammatories; Nucleosides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in France (PO)
  • 28 Jun 2011 Preclinical trials in Multiple sclerosis in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top